Long-term safety and efficacy of deferasirox (Exjade®) for up to 5years in transfusional iron-overloaded patients with sickle cell disease

British Journal of Haematology

Volumn 154, Issue 3, 2011, Pages 387-397

  Vichinsky, Elliott ^a   Bernaudin, Françoise ^b   Forni, Gian Luca ^c   Gardner, Renee ^d   Hassell, Kathryn ^e   Heeney, Matthew M ^f   Inusa, Baba ^g   Kutlar, Abdullah ^h   Lane, Peter ⁱ   Mathias, Liesl ^j,p   Porter, John ^k   Tebbi, Cameron ^l,q   Wilson, Felicia ^m   Griffel, Louis ⁿ   Deng, Wei ⁿ   Giannone, Vanessa ⁿ   Coates, Thomas ^o  

^a CHILDREN S HOSPITAL OAKLAND   (United States)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c GALLIERA HOSPITAL   (Italy)

^d LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ Children's Healthcare of Atlanta at Egleston   (United States)

^j LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

^l St Joseph's Children's Hospital of Tampa   (United States)

^m UNIVERSITY OF SOUTH ALABAMA   (United States)

ⁿ NOVARTIS PHARMA AG   (Switzerland)

^o CHILDREN S HOSPITAL LOS ANGELES   (United States)

^p Kaiser Permanente Southern California   (United States)

^q UNIVERSITY OF SOUTH FLORIDA   (United States)

more..

Author keywords

Deferasirox; Exjade; Iron overload; Oral iron chelator; Sickle cell disease

Indexed keywords

DEFERASIROX; DEFEROXAMINE; FERRITIN; HYDROXYUREA;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; APPLICATION SITE EXCORIATION; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CAUSE OF DEATH; CHILD; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; FANCONI RENOTUBULAR SYNDROME; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; GRANULOMA; HUMAN; INFLUENZA; INTOXICATION; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; KIDNEY FUNCTION; LENS DISEASE; LIMB PAIN; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; LUNG EMBOLISM; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OTALGIA; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SCHOOL CHILD; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SIDE EFFECT; SPLENECTOMY; SPONTANEOUS ABORTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TINNITUS; TREATMENT DURATION; TUBERCULOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANEMIA, SICKLE CELL; BENZOIC ACIDS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; TREATMENT OUTCOME; TRIAZOLES; YOUNG ADULT;

EID: 79960204920     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08720.x     Document Type: Article

References (38)

1. Adams, R.J. & Brambilla, D. (2005) Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New England Journal of Medicine, 353, 2769-2778.
2. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. New England Journal of Medicine, 339, 5-11.
3. Ballas, S.K. (2001) Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Seminars in Hematology, 38(Suppl. 1), 30-36.
4. Brittenham, G.M., Cohen, A.R., McLaren, C.E., Martin, M.B., Griffith, P.M., Nienhuis, A.W., Young, N.S., Allen, C.J., Farrell, D.E. & Harris, J.W. (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. American Journal of Hematology, 42, 81-85.
5. Brown, K., Subramony, C., May, W., Megason, G., Liu, H., Bishop, P., Walker, T. & Nowicki, M.J. (2009) Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy. Journal of Pediatric Hematology/oncology, 31, 309-312.
6. Cappellini, M.D., Cohen, A., Piga, A., Bejaoui, M., Perrotta, S., Agaoglu, L., Aydinok, Y., Kattamis, A., Kilinc, Y., Porter, J., Capra, M., Galanello, R., Fattoum, S., Drelichman, G., Magnano, C., Verissimo, M., Athanassiou-Metaxa, M., Giardina, B., Kourakli-Symeonidis, A., Janka-Schaub, G., Coates, T., Vermylen, C., Olivieri, N., Thuret, I., Opitz, H., Ressayre-Djaffer, C., Marks, P. & Alberti, D. (2006) A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood, 107, 3455-3462.
7. ®) in patients with β-thalassemia major treated for up to 5years. Blood, 114, Abstract 4063.
8. Cappellini, M.D., Porter, J.B., El-Beshlawy, A., Li, C.-K., Seymour, J.F., Elalfy, M., Gattermann, N., Giraudier, S., Lee, J.-W., Chan, L.L., Lin, K.-H., Rose, C., Taher, A., Thein, S.L., Viprakasit, V., Habr, D., Domokos, G., Roubert, B., Kattamis, A. & on behalf of the EPIC study investigators. (2010) Tailoring iron chelation by iron intake and serum ferritin trends: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica, 95, 557-566.
9. Charache, S., Dover, G.J., Moore, R.D., Eckert, S., Ballas, S.K., Koshy, M., Milner, P.F., Orringer, E.P., Phillips, Jr, G. & Platt, O.S. (1992) Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood, 79, 2555-2565.
10. Cockcroft, D.W. & Gault, M.H. (1976) Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31-41.
11. Cohen, A.R., Glimm, E. & Porter, J.B. (2008) Effect of transfusional iron intake on response to chelation therapy in β-thalassemia major. Blood, 111, 583-587.
12. Fung, E.B., Harmatz, P., Milet, M., Ballas, S.K., De Castro, L., Hagar, W., Owen, W., Olivieri, N., Smith-Whitley, K., Darbari, D., Wang, W. & Vichinsky, E. (2007) Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: a report from the multi-center study of iron overload. American Journal of Hematology, 82, 255-265.
13. Galanello, R., Piga, A., Forni, G.L., Bertrand, Y., Foschini, M.L., Bordone, E., Leoni, G., Lavagetto, A., Zappu, A., Longo, F., Maseruka, H., Hewson, N., Sechaud, R., Belleli, R. & Alberti, D. (2006) Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with β-thalassemia major. Haematologica, 91, 1343-1351.
14. Harmatz, P., Butensky, E., Quirolo, K., Williams, R., Ferrell, L., Moyer, T., Golden, D., Neumayr, L. & Vichinsky, E. (2000) Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood, 96, 76-79.
15. Inati, A., Musallam, K.M., Cappellini, M.D., Duca, L. & Taher, A.T. (2011) Nontransferrin-bound iron in transfused patients with sickle cell disease. International Journal of Laboratory Hematology, 33, 133-137.
16. Karam, L.B., Disco, D., Jackson, S.M., Lewin, D., McKie, V., Baker, R.D., Baker, S.S., Laver, J.H., Nietert, P.J. & Abboud, M.R. (2008) Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatric Blood Cancer, 50, 62-65.
17. Kinney, T.R., Helms, R.W., O'Branski, E.E., Ohene-Frempong, K., Wang, W., Daeschner, C., Vichinsky, E., Redding-Lallinger, R., Gee, B., Platt, O.S. & Ware, R.E. (1999) Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea group. Blood, 94, 1550-1554.
18. Kuczmarski, R.J., Ogden, C.L., Grummer-Strawn, L.M., Flegal, K.M., Guo, S.S., Wei, R., Mei, Z., Curtin, L.R., Roche, A.F. & Johnson, C.L. (2000) CDC growth charts: United States. Advance Data, 314, 1-27.
19. Marshall, W.A. & Tanner, J.M. (1969) Variations in pattern of pubertal changes in girls. Archives of Disease in Childhood, 44, 291-303.
20. Marshall, W.A. & Tanner, J.M. (1970) Variations in the pattern of pubertal changes in boys. Archives of Disease in Childhood, 45, 13-23.
21. Miller, S.T., Wright, E., Abboud, M., Berman, B., Files, B., Scher, C.D., Styles, L. & Adams, R.J. (2001) Impact of chronic transfusion on incidence of pain and acute chest syndrome during the stroke prevention trial (STOP) in sickle-cell anemia. Journal of Pediatrics, 139, 785-789.
22. National Institutes of Health NHLBI. (2002) The management of sickle cell disease. NIH Publication No 02-2117. Available at: Accessed 28 October 2010.
23. Olivieri, N.F. (2001) Progression of iron overload in sickle cell disease. Seminars in Hematology, 38(Suppl. 1), 57-62.
24. Piperno, A. (1998) Classification and diagnosis of iron overload. Haematologica, 83, 447-455.
25. Platt, O.S., Rosenstock, W. & Espeland, M.A. (1984) Influence of sickle hemoglobinopathies on growth and development. New England Journal of Medicine, 311, 7-12.
26. Porter, J.B. (2009) Pathophysiology of transfusional iron overload: contrasting patterns in thalassemia major and sickle cell disease. Hemoglobin, 33(Suppl. 1), S37-S45.
27. Porter, J., Galanello, R., Saglio, G., Neufeld, E.J., Vichinsky, E., Cappellini, M.D., Olivieri, N., Piga, A., Cunningham, M.J., Soulières, D., Gattermann, N., Tchernia, G., Maertens, J., Giardina, P., Kwiatkowski, J., Quarta, G., Jeng, M., Forni, G.L., Stadler, M., Cario, H., Debusscher, L., Della Porta, M., Cazzola, M., Greenberg, P., Alimena, G., Rabault, B., Gathmann, I., Ford, J.M., Alberti, D. & Rose, C. (2008) Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. European Journal of Haematology, 80, 168-176.
28. Schwartz, G.J., Brion, L.P. & Spitzer, A. (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatric Clinics of North America, 34, 571-590.
29. Sickle Cell Society. (2008) Standards for the clinical care of adults with sickle cell disease in the UK. Available at: Accessed 28 October 2010.
30. Smith, W.R., Penberthy, L.T., Bovbjerg, V.E., McClish, D.K., Roberts, J.D., Dahman, B., Aisiku, I.P., Levenson, J.L. & Roseff, S.D. (2008) Daily assessment of pain in adults with sickle cell disease. Annals of Internal Medicine, 148, 94-101.
31. Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D. & Terrin, M. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9years of treatment. JAMA, 289, 1645-1651.
32. Taher, A., Cappellini, M.D., Vichinsky, E., Galanello, R., Piga, A., Lawniczek, T., Clark, J., Habr, D. & Porter, J.B. (2009) Efficacy and safety of deferasirox doses of >30mg/kg per d in patients with transfusion-dependent anaemia and iron overload. British Journal of Haematology, 147, 752-759.
33. Vichinsky, E. (2001) Consensus document for transfusion-related iron overload. Seminars in Hematology, 38(Suppl. 1), 2-4.
34. Vichinsky, E., Onyekwere, O., Porter, J., Swerdlow, P., Eckman, J., Lane, P., Files, B., Hassell, K., Kelly, P., Wilson, F., Bernaudin, F., Forni, G.L., Okpala, I., Ressayre-Djaffer, C., Alberti, D., Holland, J., Marks, P., Fung, E., Fischer, R., Mueller, B.U. & Coates, T. (2007) A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. British Journal of Haematology, 136, 501-508.
35. Walter, P.B., Fung, E.B., Killilea, D.W., Jiang, Q., Hudes, M., Madden, J., Porter, J., Evans, P., Vichinsky, E. & Harmatz, P. (2006) Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease. British Journal of Haematology, 135, 254-263.
36. Walter, P.B., Harmatz, P. & Vichinsky, E. (2009) Iron metabolism and iron chelation in sickle cell disease. Acta Haematologica, 122, 174-183.
37. Wang, W.C., Morales, K.H., Scher, C.D., Styles, L., Olivieri, N., Adams, R. & Brambilla, D. (2005) Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. Journal of Pediatrics, 147, 244-247.
38. Wun, T. & Hassell, K. (2009) Best practices for transfusion for patients with sickle cell disease. Hematology Reviews, 1, 106-110.